Clinical trial · Interventional
Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer
Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer: A Randomized, Double-blinded, Placebo-controlled Trial
NCT05754801CI-TRIAL-00119831recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Palliative Care | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Other | — | UNRESOLVED |
| Yunzhi Essence | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Active treatment (Yunzhi Essence)
- description
- Subjects will take 2 Yunzhi capsules, 4 times daily, for 6 months.
- interventionNames
- Drug: Yunzhi Essence
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Subjects will take 2 placebo capsules, 4 times daily, for 6 months
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Score change of McGilll QOL-Hong Kong
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed with advanced cancer according to the definition from American Cancer Society; * According to the experience of the doctor, by using Palliative Prognostic Index (score\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years; * Abbreviated mental test (AMT) score of 6 or above; * Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient); * Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes/patterns, syndrome of "damp heat spleen" and "spleen deficiency with water stop" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms). Exclusion Criteria: * Patients with a history of allergy to traditional Chinese medicine or Yunzhi; * Patients who required nasal feeding or difficulty swallowing; * Patients with comatose/semi-conscious, cognitively impaired with dementia/confusion, physically too ill with extremely poor general condition, or there was a language barrier.
References
Publications (0)
Data not yet available
No reference posted for this study.